Oramed Pharmaceuticals Inc.
ORMP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.13
KIRA · Stoqly’s AI analyst, in plain words
- Oramed Pharmaceuticals Inc. had $2.0M of revenue in fiscal 2025. Over five years, revenue changed −5.9% a year on average.
- Its operating margin was −754.4%: of every 100 in sales, about −754 is left after running the business.
- Oramed Pharmaceuticals Inc. made $64.1M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 6.2% a year.
- Free cash flow was −$9.2M in fiscal 2025, −457.7% of revenue.
- Oramed Pharmaceuticals Inc. returned $4.7M to shareholders in fiscal 2025. The diluted share count rose 3.8%.
Market cap
$176M
P/E
1.0x
Revenue
$2.0M
Net income
$64.1M
Free cash flow
−$9.2M
Operating margin
−754.4%
Oramed Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Does it make a profit?
3,202.5%
Yes. It keeps 3,202.5% of every sale as profit.
Does profit turn into cash?
−457.7%
No. It spent more cash than it brought in.
How is the share priced?
1.0x
One share costs 1.0 times its yearly profit per share.
What Oramed Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- ORAMED PHARMACEUTICALS INC.
- CIK
- 0001176309
Oramed Pharmaceuticals Inc. · ORMP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.7M | — | $1.3M | — | $2.0M |
| Revenue growth | −0.3% | — | — | — | — |
| Gross margin | — | — | — | — | 0.7% |
| Operating margin | −896.2% | — | −1,176.8% | — | −754.4% |
| Net income | −$23.0M | — | $5.1M | −$19.1M | $64.1M |
| Net margin | −850.5% | — | 379.7% | — | 3,202.5% |
| Diluted EPS | $0.78 | — | $0.14 | −$0.48 | $1.50 |
| Cash | |||||
| Cash from operations | −$21.2M | — | −$10.3M | −$8.4M | −$9.1M |
| Capital expenditure | $0.4M | — | $0.3M | $0.0M | $0.0M |
| Free cash flow | −$21.6M | — | −$10.5M | −$8.4M | −$9.2M |
| FCF margin | −797.5% | — | −787.2% | — | −457.7% |
| Share buybacks | — | — | — | $2.5M | $4.7M |
| Share count change | 38.7% | — | — | 0.7% | 3.8% |
| Debt and strength | |||||
| Cash and short-term investments | $83.1M | $44.2M | $66.8M | $57.9M | $51.4M |
| Debt incl. finance leases | $12.5M | $0.0M | $51.0M | — | — |
| Shareholders' equity | $116M | $152M | $164M | $146M | $200M |
| Current ratio | 14.3x | 27.3x | 3.1x | 25.2x | 7.0x |
| Interest coverage | — | — | −7.7x | −15.0x | — |
| Returns and quality | |||||
| Return on capital | −42.3% | — | −8.4% | — | — |
| Return on equity | −30.9% | — | 3.2% | −12.3% | 37.0% |
| Return on tangible equity | 19.9% | — | 3.1% | −13.0% | 31.7% |
| Piotroski F-score | 3 | — | — | — | — |
| Altman Z'' | 10.3 | — | 3.5 | 18.6 | 7.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.2M
2 insiders
Of sales under plans
100%
$1.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Oramed Pharmaceuticals Inc. · ORMP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.13 a share, the company is worth $176M: 1.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001176309). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.